Muscle Precursor Cell (MPC) Therapy for treatment of stress urinary incontinence in women

In the SUISSE MPC 2 study (Stress Urinary Incontinence Study to assess Safety and Efficacy of Muvon’s Muscle Precursor Cell Therapy), researchers at the University of Zurich are currently investigating a novel treatment option. This is a so-called “Phase II study”, which is designed to assess the efficacy and safety of the new treatment option.

Muvon Therapeutics is urgently looking for patients who are willing to take part in this trial in Switzerland.

It is a novel treatment under development that uses the patient’s own muscle precursor cells to regenerate the damaged urinary sphincter muscle aiming to improve the condition without the use of implanted synthetic material and surgery with possible associated complications.

Please find below some information about this study in German

Who is it for?

  • Women who find that first-line treatments don’t significantly improve incontinence
  • Women suffering from stress urinary incontinence

What does it involve?

The MPC Therapy is a novel regenerative approach which aims to improve the symptoms of stress urinary incontinence without the use of synthetic material.

  • In a first step, a small muscle biopsy is obtained from the calf of the patient.
  • Muscle precursor cells are isolated from the collected material in the laboratory and are then multiplied in an incubator.
  • Following rigorous quality testing the product is released and brought to the hospital for injection, where it is injected into the sphincter muscle of the patient, with the aim of regenerating the muscle and consequently improving symptoms.

How can I find out more?

For more information on the treatment and the phase II clinical trial investigating its safety and efficacy please watch the following video or visit

Where can I go for treatment?

The safety and efficacy of the MPC Therapy is currently being investigated in a phase II clinical trial at the University Hospital in Zurich. To find out more and check your eligibility for joining the trial please visit.